

Conflict of interests ?

- In Lausanne, we use a Bruker mass spectrometer but we have no conflict of interest with Bruker

Relationship with industry

- Research grant with **SUEZ-ONDEO** (France)

CHUV

1. What is MALDI-TOF ?

Mass spectrometers

- 1. Ion source**
transfer molecules into a gas phase
- 2. Mass analyzer**
separate ions according to their mass to charge ratio (m/z)
- 3. Detection device**
monitor amount separated ions

Croxatto, Prod'hom & Greub, FEMS Microbiol Reviews 2011

CHUV

1. What is MALDI-TOF ?

Ionization methods

1. Plasma desorption (PD)
2. Fast atom bombardment (FAB)
3. Chemical ionization (CI)
4. Atmospheric pressure CI
5. Laser desorption
6. Electrospray ionization (ESI)
7. MALDI

}

Bacterial lipids

}

Intact proteins

Croxatto, Prod'hom & Greub, FEMS Microbiol Reviews 2011

Table

1. What is Maldi-tof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions

Croxatto, Prod'hom & Greub, FEMS Microbiol Reviews 2011

1. What is MALDI-TOF ?

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)

Intensity

Result (spectrum)

Detector

Detection

Flight tube

Separation Time-of-Flight (no electric field)

Acceleration (electrostatic field)

Laser

Matrix-assisted laser desorption ionization

Adapted from: Croxatto, Prod'hom & Greub, FEMS Microbiol Reviews 2011

1. What is MALDI-TOF ?

Different spectra will be obtained for different microbial species

S. aureus

E. faecium

E. coli

with spikes ranging from 1'000 to 20'000 m/z

CUV

1. What is MALDI-TOF ?

About 50% of detected proteins are ribosomal proteins

Ribosomal proteins	m/z
SLP	4564.33
SLP	5036.51
SLP	5382.39
SLP	5426.58
SLP	6115.19
SLP	6458.28
SLP	7275.45
SLP	7675.06
SLP	8260.16
SLP	8300.99

E. coli

organic solvents and acidic conditions used for lysis are favouring extraction of ribosomal proteins, which are abundant and basic

Source: 2004

CUV

1. What is MALDI-TOF ?

About 50% of detected proteins are ribosomal proteins

Others proteins (*Salmonella*) include:

- Cold shock-like protein (Csph)
- Translation initiation factor IF-1
- Ribosome modulation factor
- Integration host factors A & B
- Nucleoid-associated proteins H-NS
- RNA chaperone CspeE
- Glutaredoxin-1
- Phosphocarrier protein HPr

pl > 9

Abundant

= abundant and basic

Dieckmann et al. Appl Env Microbiol 2008


CUV

1. What is MALDI-TOF ?

Commonly used matrices



2,5 dihydroxybenzoic acid (DHB)	}	Glycoproteins glycopeptides
Alpha-cyano-4-hydroxycinnamic acid (CHCA)		
Sinapinic acid (SA)	}	Proteins
Ferulic acid (FA)		
2,4 hydroxyphenylbezoic acid		

**1.5 microl CHCA
in 50% acetonitrile/2.5% trifluoroacetate**




1. What is MALDI-TOF ?

Identification procedure




1. What is MALDI-TOF ?

Identification procedure



Comparison with a database

1. Mass spectra comparison with fingerprints database
 - rapid, simple
 - applicable in diagnostic lab
2. Matching of biomarkers masses to a proteome database
 - most moelcules > 4000 Da are proteins
 - in silico prediction of mass from genomes data
 - tolerates variation in culture conditions/samples prep.



1. What is MALDI-TOF ?

Comparison with references spectra

Score > 2
Score 1.7-2
Score < 1.7

MALDI Biotyper User Manual, Version 2.0 (Bruker)

Score = function (database; spectra; ...)

Table

1. What is Maldi-tof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions

2. Routine identification of bacterial isolate

Identification of bacterial isolate (n=1371)

- Scores

– Valid (≥ 2)	1278	93.2%
– Intermediate (1.7-2)	73	5.3%
– No identification (<1.7)	20	1.5%
- Identification (among scores >2)

– Correct at species level	1215/1278	95.1%
– Correct at genus level	39/1278	3%
– Discordant results	24/1278	1.9%

Bizzini et al. J Clin Microbiol (2010)

2. Routine identification of bacterial isolate

Quality of the database

Errors in the reference spectra
Propionibacterium acnes wrongly identified as *Eubacterium brachy*

Similarities of spectra present in the database
Klebsiella oxytoca and *Raoultella planticola* ...

Absence of reference spectra in the database
 No spectra of non-*Clostridium anaerobes*

Insufficient number of reference spectra in the database
 Only 1 spectrum of *Propionibacterium acnes* or *Bacillus cereus*
 Not enough to be representative of the true diversity of their profiles

Taxonomical "errors" in the database
Stenotrophomonas maltophilia misidentified
 as *Pseudomonas hibiscicola*

Taxonomical "discordances" with common use
Agrobacterium tumefaciens is a synonym of *Rhizobium rhizogenes*
Enterobacter cloacae (group) versus *Enterobacter hormaechei*

Croxatto, Prod'hom & Greub, FEMS Microbiology Reviews 2011

2. Routine identification of bacterial isolate

Discriminatory power of MALDI-TOF insufficient to differentiate closely related species

Even with good spectra (definition of species)
E. coli and *Shigella* spp.

Especially with spectra of slightly lowered quality, (partially also due to limited number of spectra)

Streptococcus pneumoniae and *Streptococcus mitis*
Streptococcus pneumoniae and *Streptococcus parasanguinis*
Streptococcus constellatus versus *Streptococcus anginosus*
Streptococcus pyogenes versus *Streptococcus dysgalactiae*
 ...
Klebsiella oxytoca and *Raoultella planticola*, ...

Croxatto, Prod'hom & Greub, FEMS Microbiology Reviews 2011

2. Routine identification: benefits from database extension

Benefits of database extension (1)

Gemella, Granulicatella, Abiotrophia
 Christensen JJ
 J Clin Microbiol. 2012 May;50(5):1787-91

Anaerobes:
 - 179/253 (70.8%) correct identific. at species level
 - 232/253 (91.7%) correct identific. at genus level

Schmitt BH.
 J Clin Microbiol 2013; 51:782-6.

Spirochetes:
Identification of human & animal *Brachyspira* species (anaerobes of the intestinal tract)

Calderaro A et al.
 J Proteomics. 2013 Jan 14;78:273-80.

2. Routine identification: benefits from database extension


Benefits of database extension (2)

Prevotella spp.

Extension of the commercial database improved identification rate at species level from 62.7% (of 102 isolates) to 83.3%

Wybo I. et al. J Clin Microbiol. 2012 Apr;50(4):1415-8.

Useful to have an international shared extended curated non-commercial database



2. Routine identification: benefits from database extension

Importance of having a complete database

Anthrax infection in an injecting drug user in Germany
Anthrax was not suspected initially: the patient died

Day 1

- Patient admitted to the hospital
- Blood cultures sent to the laboratory
- Patient dies due to septic shock
- Blood cultures positive with Gram-positive bacilli (late afternoon)

Day 2

- Growth of *Bacillus* spp. on subcultures
- MALDI-TOF: *Bacillus cereus* → **Retrospectively identified as *B. anthracis***
- Discussions on anthrax suspicion
- Different PCRs and 16S sequencing over night

Day 3

- *B. anthracis* confirmed by PCR


Fatal anthrax infection in a heroin user from southern Germany, June 2012. Holzmann T et al. Euro Surveill. 2012 Jun 28;17(26).




2. Routine identification: reduced time to identification (TTI)


Prospective study


Reduced time to identification



Tan KE et al. J Clin Microbiol. 2012 Oct;50(10):3301-8







3. Quality control: importance of negative controls

MALDI microplates

Problems:
Residues of proteins ? Inadequate cleaning?


Quality control
Visual inspection
Negative controls at each run
Occasionally check microplates by applying the matrix on all 96 wells after routine wash
⇒ Disposable MALDI microplates

2. Routine identification: quality controls & maintenance

Calibration
«BTS» control

E. coli
(RL36, RS32, RS34,
RS33, RL29, RS19)

RNase A
Myoglobin




2. Routine identification: quality controls & maintenance

Problems:

- 1. vacuum failure
 - dust on plastic joints
 - loss of etancheity of the plastic joints

- 2. carbonisation of bacteria (laser may be soiled)



Croxatto, Prod'homme & Greub, FEMS Microbiology Reviews 2011

2. Routine identification: quality controls & maintenance

Maintenance
1x/3 months in Lausanne
(~ 5 run/days)



2. Routine identification: reproducibility

Reproducibility

Most data available from clinical chemistry

Duplicate of 5 samples
In the left hand panel, the first technical replicate is shown with the black solid line and the second technical replicate with the red dotted line

Cairns D.A. et al. BMC bioinformatics 2008; 9: 519

2. Routine identification: reproducibility

Reproducibility

E. coli 10⁶ *S. aureus* 10⁶

█ 1 extraction - 10 replicates
□ 10 extractions - 1 replicate

→ Variability is mainly due to the deposit (high reproducibility of extraction)

Croxatto, Prod'hom & Greub, FEMS Microbiology Reviews 2011

2. Routine identification: reproducibility

Temporal reproducibility

S. aureus 10⁶ bacteria/well

Scores always 2.3-2.5

↓

Do not only rely on scores

- check spectra
- use other strains, other algorithms,...

Croxatto, Prod'hom & Greub, FEMS Microbiology Reviews 2011

2. Routine identification: cost analysis

Cost analysis (1371 isolates)
assuming cost of technician time of 1.2 €/min

	with MALDI-TOF*	without MALDI-TOF
mean cost	4.03€	9.43€
annual cost	71'921€	168'094€


→ **2.34 fold reduction**

Including acquisition (5 year amortization) & maintenance

	132'521€	168'094€
--	----------	----------

→ **1.27 fold reduction**


*identification by MALDI-TOF and when needed additional approaches
Heininger, Prod'hom & Greub, in preparation




Table

1. What is Malditof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions

Heininger, Prod'hom & Greub, in preparation







Table

1. What is MALDI-TOF ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases & toxins
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions

© by author





4. Detection of carbapenemases

Modified test
using a 10 microg ertapenem disk; only 1 hour incubation

Diagnostic approach	Sensitivity	Specificity
Phenotypic detection (Modified Hodge test)	90.5% (19/21)	86% (24/28)
Phenotypic detection (IP/IP)*	54.5% (6/11)	92.1% (35/38)
PCR-Check MDR Carba	90.5% (19/21)	100% (28/28)
Microarray	90.5% (19/21)	100% (28/28)
MALDI-TOF	100% (21/21)	100% (28/28)
MS/MS	100% (21/21)	100% (28/28)

*phenotypic detection of metallo- β -lactamases (VIM, IMP, NDM)



Vogne *et al.*, submitted

Table

1. What is MALDI-tof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions




5. Direct identification from positive blood cultures



5. Direct identification from positive blood cultures

Direct identification from positive blood cultures



5. Direct identification from positive blood cultures

Pellet preparation

Initial centrifugation (1'000 x g for 10 min)

Erythrocytes lysis with ammonium chloride (left tube) or with NaCl control (right tube)

Ammonium procedure NaCl control

Patented

Prod'hom et al. J Clin Microbiol (2010)

5. Direct identification from positive blood cultures

Results

Excellent accuracy

n=122
 69(57%) > 2.0
 96(79%) > 1.7
 1 discordant
S. caprae vs *S. pasteurii*

Prod'hom et al. J Clin Microbiol (2010)

5. Direct identification from positive blood cultures

Overview of the litterature

Authors (year)	n	Concordant ID at species level
Prod'hom (2010)	126	78% (GN: 89%, GP: 72%)
Prod'hom (unpublished)	314	85% (GN: 89%, GP: 83%)
La Scola (2009)	599	66% (GN: 91%, GP: 49%*)
Ferreira 2010	300	43% (GN: 83%, GP: 32%)
Stevenson (2010)	212	80%
Ferroni (2010)	685	89% (312 spiked bottles)
Christner (2010)	277	94%
Ferreira (2010)	68	76%


*Improved extraction for *Staphylococcus* spp.: 38 to 75%

Croxatto, Prod'hom & Greub. FEMS Microbiol Rev 2011

5. Direct identification from positive blood cultures

Applications of the pellet

Authors (year)	n	Concordant ID at species level
Prod'hom (2010)	122	78% (GN: 89%, GP: 72%)
Prod'hom (unpublished)	314	85% (GN: 89%, GP: 83%) <small>Prod'hom et al, in prep.</small>



Patented

Vitek AST → **Major errors**
0.4% for Gram neg.
0.8% for *Staphyloc.*

GenXprt MRSA → **Randomized trial**
(18 months; impact on vancomycin use)

Prod'hom et al, J Med Microbiol 2013

Clerc et al, Clin Microbiol Infect 2013

5. Direct identification from positive blood cultures

Direct identification from blood cultures

Several studies from 2009-2012

- Adequate bacterial concentration is needed
- Removal of red blood cells, blood proteins, ...
- Overall success rate ranging from **65 to 85%** using SDS, saponin, Tween, MALDI- Sepsityper, ...

Differential centrifugation protocol:

- identification available & reliable in :
97.3 for Gram negative bacteria
98.4% for Gram positive bacteria

March-Rosello et al
Eur J Clin Microbiol Infect Dis 2013

5. Direct identification from positive blood cultures

«no reliable identification» for 26 bottles

Factors possibly affecting MALDI-TOF MS efficiency


Presence of a capsule
 - *K. pneumoniae*, *H. influenzae*, *S. pneumoniae* (n=13)

Close relatedness of bacteria within streptococci
 - *S. pneumoniae*, *S. oralis*, ... (n=13)

Cell wall composition of Gram positive bacteria conferring high resistance to lysis (n=21)

Presence of residual blood proteins ? } **quality control**
 Inadequate procedure ? }

Prod'hom et al. J Clin Microbiol (2010)



5. Direct identification from positive blood cultures

Expected clinical impact:

- reduced time to results
- blood culture >> other identifications

- Gram positive bacteria in chains: Possible impact on:
Streptococci vs *Enterococci* Investigations, treatment.
E. faecium vs *E. faecalis* Treatment

- Gram positive cocci in cluster: Clinical significance
S. aureus vs *S. lugdunensis*,
S. epidermidis, ...

- Gram negative bacteria
E. coli / *Klebsiella* vs Gram negative bacteria such as
Serratia marcescens, *Morganella morganii* and *Enterobacter cloacae*
 encoding on their chromosome an inducible cephalosporinase

Non fermentative bacteria Treatment

Table

1. What is Maldit-tof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. Conclusions

6. Clinical impact of MALDI-TOF

Impact of MALDI-TOF: retrospective study

- Time to identification
1h35 with MALDI-TOF (versus 25h43 without)

Clinical impact:

- 20/157 results led to a treatment change (in adults)
- 1/ 40 results led to a treatment change (in children)

Martiny et al. Clin Microbiol Infect 2013

6. Clinical impact of MALDI-TOF

Impact of MALDI-TOF: retrospective study





- Time to identification
1h35 with MALDI-TOF (versus 25h43 without)

Clinical impact:

- 20/157 results led to a treatment change (in adults)
- 1/ 40 results led to a treatment change (in children)
- New blood cultures (n=2)
- Catheter removal (n=4)
- Additionnal investigations (n=3)
- Documented sample exchange (n=1)
- Exclude a contamination
(38% in pediairy; 9% for adults)

Martiny et al. Clin Microbiol Infect 2013

4. Direct identification from positive blood cultures

Pre-MALDI-TOF era	Post-MALDI-TOF era
 Gram + cocci arranged in chains	
 Gram + cocci arranged in pairs	

CLINICAL IMPACT OF REDUCED TIME TO IDENTIFICATION ?

Impact on AB adequacy in 35% (63/202) of cases

Clerc et al. Clin Infect Dis 2013

E. coli

Day 0
Day 1

S. aureus *E. coli*

Table

1. What is Maldi-tof ?
2. Routine identification of bacterial isolate
3. Identification of « difficult to identify strains »
4. Detection of carbapenemases
5. Direct identification from positive blood cultures
6. Clinical impact of MALDI-TOF
7. **Conclusions**


CDU

7. Conclusions

BACTERIAL IDENTIFICATION
is one of the major application of MALDI-TOF

- Excellent identification method
- Applicable to blood culture pellet
- Rapid (< 1h)
- Cheap and accurate
- Need for improved database
- Clinical impact

CDU



Thank you



Thank you

- Sébastien Aeby
- Alain Bizzini
- Myriam Corthesy
- Antony Croxatto
- Christian Durussel
- Philippe Hauser
- Samuel Heiniger
- Aude Leresche
- Julia Lienard
- Guy Prod'hom
- Nathalie Ramirez
- Anna Ruegger
- Laurence Simon
- Gizna Shkqim
- Christelle Vogne






Impact of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry on the Clinical Management of Patients With Gram-negative Bacteremia: A Prospective Observational Study

Olivier Clerc,¹ Guy Prod'homme,² Christelle Vogne,² Alain Bizzini,² Thierry Calandra,¹ and Gilbert Greub^{1,2}
¹Infectious Diseases Service and ²Institute of Microbiology, Lausanne University Hospital Center and University of Lausanne, Switzerland

Clerc et al. Clin Infect Dis 2013




6. Clinical impact of MALDI-TOF



Clerc et al. Clin Infect Dis 2013



6. Clinical impact of MALDI-TOF



Clerc et al. Clin Infect Dis 2013



6. Clinical impact of MALDI-TOF

Impact of the Sequential Reporting		N = 202
Gram stain		42 (20.8)
Streamlining		16 (7.9)
Spectrum broadening		16 (7.9)
Introduction of empirical antibiotic therapy		10 (5.0)
MALDI-TOF MS		71 (35.1)
Streamlining		22 (10.9)
Spectrum broadening		31 (15.3)
Introduction of focused empirical antibiotic therapy		18 (8.9)


Impact of MALDI-TOF on empirical antibiotic therapy in 35% of bacteremia

Clerc et al. Clin Infect Dis 2013

6. Clinical impact of MALDI-TOF

MALDI-TOF MS and POCT-PCR for the Rapid Diagnosis of *Staphylococcus aureus* Bacteremia:

- Randomized trial with/without POCT-PCR (n=197)
- 95% of *S. aureus* identification in blood cultures with MALDI-TOF



Clerc et al. Clin Microbiol Infect 2013

6. Clinical impact of MALDI-TOF

MALDI-TOF MS and POCT-PCR for the Rapid Diagnosis of *Staphylococcus aureus* Bacteremia:

- Randomized trial with/without POCT-PCR (n=197)
- 95% of *S. aureus* identification in blood cultures with MALDI-TOF

GenXpert on blood cultures - 106 cases

<p>24 episodes of MRSA (1 polymicrobial)</p> <ul style="list-style-type: none"> - All correctly identified - No false-positive result 	} Specificity 100% Sensitivity 99%
<p>82 episodes of MSSA (1 polymicrobial)</p> <ul style="list-style-type: none"> - 81 correctly identified, 1 undetermined 	

Clerc et al. Clin Microbiol Infect 2013

6. Clinical impact of MALDI-TOF

Time to result

- **Positive blood culture → MALDI-TOF**
Median time 104 minutes
- **MALDI-TOF → GenXpert**
Median time 97 minutes

} **201 minutes**

Clerc et al. Clin Microbiol Infect 2013

6. Clinical impact of MALDI-TOF

Time to result

- **Positive blood culture → MALDI-TOF**
Median time 104 minutes
- **MALDI-TOF → GenXpert**
Median time 97 minutes

} **201 minutes**

Clinical impact

	Intervention N = 106		Standard N = 91	
	MRSA n = 24	MSSA n = 82	MRSA n = 19	MSSA n = 72
MRSA carriers	18 (75)	1 (1.2)	16 (84.2)	1 (1.4)
Anti-MRSA treatment	22 (91.7)	14 (17.1)*	18 (94.7)	21 (29.2)*

* P = 0.09, Fisher's exact test

Clerc et al. Clin Microbiol Infect 2013

6. Clinical impact of MALDI-TOF

Summary

- 95% of correct *Staph. aureus* identification in blood cultures with MALDI-TOF
- High performances of **GenXpert on positive blood cultures**
- **Clinical impact:**
 - Reduced unnecessary coverage of MRSA in cases of MSSA bacteremia (17% versus 29%)
 - Early diagnosis of unsuspected MRSA bacteremia

➔ **MALDI-TOF done routinely on all blood cultures since 2009**

➔ **POCT-PCR MRSA done on all *S. aureus* blood culture (from patients not known to be MRSA carriers)**

Clerc et al. Clin Microbiol Infect 2013
